Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma’s ambitious pipeline touches dozens of rare genetic diseases, which means each SEC document is dense with trial data, cash-runway tables and licensing terms. If you have ever typed “BridgeBio Pharma SEC filings explained simply” or hunted through a 200-page report for one orphan-drug update, you know how time-consuming it can be.
Stock Titan solves that problem. Our AI engine turns the company’s most complex disclosures into plain-language insights. Open a BridgeBio Pharma annual report 10-K simplified or drill into a BridgeBio Pharma quarterly earnings report 10-Q filing—key figures, pipeline timelines and risk factors are highlighted automatically. Material news drops? A BridgeBio Pharma 8-K material events explained alert lands in your dashboard within seconds. Need trading color? We stream BridgeBio Pharma Form 4 insider transactions real-time so you never miss executive stock moves.
Here’s what you can uncover in seconds:
- Cash usage trends and dilution impact through BridgeBio Pharma earnings report filing analysis.
- Pipeline milestones linked to specific clinical programs, flagged across multiple forms.
- BridgeBio Pharma executive stock transactions Form 4 and broader insider trading Form 4 transactions for sentiment checks.
- BridgeBio Pharma proxy statement executive compensation details, including option grants and performance metrics.
Whether you’re understanding BridgeBio Pharma SEC documents with AI for the first time or monitoring seasoned positions, every filing type—10-K, 10-Q, 8-K, S-1, SC 13D and more—updates in real time from EDGAR. Spend less time scrolling and more time acting on the genetic-medicine data that moves the market.
BridgeBio Pharma (NASDAQ: BBIO) filed a Form 4 disclosing that director Frank P. McCormick sold 100,000 common shares on 06/24/2025 under a pre-arranged Rule 10b5-1 plan.
The shares were sold at a weighted-average price of $44.23, generating proceeds of roughly $4.4 million.
Following the sale, McCormick owns 879,979 shares indirectly through his revocable trust and 83,275 shares directly, implying the transaction reduced his total position by about 9-10%.
No derivative securities were involved and no other insiders were party to the filing.
BridgeBio Pharma Form 144 Notice filed on June 28, 2025, details a proposed sale of securities by Denis Von Kaeppler IRA Rollover, who is related to the company through their wife's Board of Directors position.
Key transaction details:
- Securities to be sold: 1,891 shares of common stock
- Aggregate market value: $83,261.30
- Planned sale date: June 26, 2025 on NASDAQ
- Broker: Morgan Stanley Smith Barney LLC
The shares were originally acquired through an open market purchase on December 28, 2021. Notable recent insider activity includes multiple sales by Hannah Valantine, who sold a total of 17,168 shares for approximately $686,334 in gross proceeds on June 10, 2025. The company has approximately 189.9 million shares outstanding.
BridgeBio Pharma (BBIO) Director Andrew Lo reported new equity grants on June 20, 2025. The insider received:
- 6,589 Restricted Stock Units (RSUs) with zero acquisition cost, vesting over three years through June 20, 2028
- 8,425 Stock Options with a strike price of $41.73, exercisable until June 19, 2035, also vesting over three years
Following these transactions, Lo owns 54,688 shares directly and 105,583 shares indirectly through joint ownership with Nancy N. Lo. The equity grants are subject to continued service on the board. These awards were granted under the company's 2021 Amended and Restated Stock Option and Incentive Plan, representing standard director compensation rather than open market transactions.
BridgeBio Pharma director Andrea Ellis received new equity compensation grants on June 20, 2025, consisting of two components:
- 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, increasing total direct stock ownership to 18,589 shares
- 8,425 Stock Options with an exercise price of $41.73 and expiration date of June 19, 2035
Both grants follow a 3-year vesting schedule with one-third vesting annually starting June 20, 2025, contingent on continued board service through June 20, 2028. The equity awards were issued under the company's 2021 Amended and Restated Stock Option and Incentive Plan, representing standard director compensation aligned with long-term shareholder interests.
BridgeBio Pharma director Jennifer E. Cook received new equity compensation grants on June 20, 2025, consisting of:
- 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, bringing her total direct RSU ownership to 13,741 shares
- 8,425 Stock Options with an exercise price of $41.73 per share, expiring June 19, 2035
Both grants follow a 3-year vesting schedule with one-third vesting each year starting June 20, 2025, and completing on June 20, 2028. Vesting is contingent on Cook's continued service as a director. This Form 4 filing, signed on June 24, 2025, reflects standard equity compensation for non-employee directors and demonstrates the company's approach to aligning director interests with shareholders through long-term equity incentives.
BridgeBio Pharma Director Frank McCormick reported multiple equity transactions on June 20, 2025:
- Received 6,589 Restricted Stock Units (RSUs) with $0 exercise price, vesting over 3 years through June 20, 2028
- Granted 8,425 stock options with $41.73 exercise price, vesting over 3 years through June 20, 2028 and expiring June 19, 2035
- Currently holds 979,979 shares indirectly through the Francis P. McCormick Rev Trust
Both RSUs and options are subject to continued service on BridgeBio's board of directors. The grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting.
BridgeBio Pharma Director Eric Aguiar reported two significant equity transactions on June 20, 2025:
- Restricted Stock Units (RSUs): Acquired 6,589 RSUs at $0 cost, which vest over three years through June 20, 2028
- Stock Options: Received 8,425 options with exercise price of $41.73, vesting over three years and expiring June 19, 2035
Both grants are subject to Aguiar's continued service on BridgeBio's board of directors, with annual vesting of one-third of the awards. The RSUs represent contingent rights to receive common stock shares upon vesting. This compensation package aligns the director's interests with long-term shareholder value through a combination of time-based RSUs and options with a significant exercise price.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
What is BridgeBio Pharma's core business?
How does BridgeBio Pharma differentiate itself from other biopharmaceutical companies?
What types of diseases does BridgeBio focus on?
What is the significance of the portfolio-based strategy employed by BridgeBio?
How does BridgeBio Pharma ensure the credibility of its drug development programs?
What role does genetic innovation play in BridgeBio's strategy?
How is BridgeBio Pharma positioned within the competitive biopharmaceutical market?
What kind of expertise supports BridgeBio Pharma's operations?
